Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa

Author(s): Roberta Giuffrida, Serafinella Patrizia Cannavò, Marialorena Coppola, Claudio Guarneri*

Journal Name: Current Pharmaceutical Biotechnology

Volume 22 , Issue 1 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Hidradenitis Suppurativa (HS) is a chronic, recurrent and disabling inflammatory skin condition, clinically characterized by nodules, bullae, abscesses, fistulae, and draining sinus tracts mainly located in axillae, inguinal folds, inframammary region and buttocks, often leading to pain, scarring, disfigurement and decreased quality of life. Due to its complex nature, with still no completely elucidated etiology and pathogenesis, the management of HS can be challenging. In fact, many patients do not respond to the traditionally available systemic treatments, including antiinflammatories, antibiotics and surgery. Research has provided new insights into the mechanisms of HS, mainly investigating the inflammatory cytokine pathways underlying the disease.

Methods: We review the current knowledge on newer therapeutic approaches and targets for the treatment of HS, through a PubMed-based literature search.

Results: In this setting, studies on tumor necrosis factor-α, IL-1β, IL-10, and the IL-23/T-helper (Th) 17 and IL12/Th1 axes in immune dysregulation in HS have helped in developing new regimens. Inhibitor of phosphodiesterase 4 and laser treatments have shown clinically meaningful efficacy with good short-term safety and tolerability.

Conclusion: Target therapy has revolutionized the treatment of moderate to severe HS, based on the inhibition of specific molecular or cellular targets, directly involved in the pathogenesis of the condition.

Keywords: Hidradenitis suppurativa, acne inversa, therapy, biologics, anti-TNF alpha, anti-IL-1, anti-IL-17, anti-IL-23.

[1]
Negus, D.; Ahn, C.; Huang, W. An update on the pathogenesis of hidradenitis suppurativa: Implications for therapy. Expert Rev.Clin. Immunol., 2018, 14(4), 275-283.
[http://dx.doi.org/10.1080/1744666X.2018.1449647] [PMID: 29509041]
[2]
Ballard, K.; Shuman, V.L. Hidradenitis Suppurativa.2019 In:StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. 2020 Aug 10; http://www.ncbi.nlm.nih.gov/books/NBK534867/
[3]
Vinkel, C.; Thomsen, S.F. Hidradenitis suppurativa: Causes, features, and current treatments. J. Clin. Aesthet. Dermatol., 2018, 11(10), 17-23.
[PMID: 30519375]
[4]
Matusiak, Ł.; Jemec, G.B.; Szepietowski, J.C. Pharmacological development in hidradenitis suppurativa. Curr. Opin. Pharmacol., 2019, 46, 65-72.
[http://dx.doi.org/10.1016/j.coph.2019.04.006] [PMID: 31075754]
[5]
Frew, J.W.; Hawkes, J.E.; Krueger, J.G. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa. F1000 Res., 2018, 7, 1930.
[http://dx.doi.org/10.12688/f1000research.17267.1] [PMID: 30828428]
[6]
Lee, E.Y.; Alhusayen, R.; Lansang, P.; Shear, N.; Yeung, J. What is hidradenitis suppurativa? Can. Fam. Physician, 2017, 63(2), 114-120.
[PMID: 28209676]
[7]
Li, A.; Peng, Y.; Taiclet, L.M.; Tanzi, R.E. Analysis of hidradenitis suppurativa-linked mutations in four genes and the effects of PSEN1-P242LfsX11 on cytokine and chemokine expression in macrophages. Hum. Mol. Genet., 2019, 28(7), 1173-1182.
[http://dx.doi.org/10.1093/hmg/ddy414] [PMID: 30544224]
[8]
Marzano, A.V.; Trevisan, V.; Gattorno, M.; Ceccherini, I.; De Simone, C.; Crosti, C. Pyogenic arthritis, Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa (PAPASH): A new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol., 2013, 149(6), 762-764.
[http://dx.doi.org/10.1001/jamadermatol.2013.2907] [PMID: 23571383]
[9]
Braun-Falco, M.; Kovnerystyy, O.; Lohse, P.; Ruzicka, T. Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J. Am. Acad. Dermatol., 2012, 66(3), 409-415.
[http://dx.doi.org/10.1016/j.jaad.2010.12.025] [PMID: 21745697]
[10]
Cintolo, M.; Guarneri, C.; Lentini, M. A case of molluscum contagiosum infection in a patient with Crohn’s disease, receiving combination therapy with azathioprine and adalimumab. J. Crohn’s Colitis, 2015, 9(7), 593-594.
[http://dx.doi.org/10.1093/ecco-jcc/jjv069] [PMID: 25908722]
[11]
Dattilo, G.; Imbalzano, E.; Casale, M.; Guarneri, C.; Borgia, F.; Mondello, S.; Laganà, P.; Romano, P.; Oreto, G.; Cannavò, S. Psoriasis and cardiovascular risk: Correlation between psoriasis and cardiovascular functional indices. Angiology, 2018, 69(1), 31-37.
[http://dx.doi.org/10.1177/0003319717699329] [PMID: 29212353]
[12]
Alikhan, A.; Lynch, P.J.; Eisen, D.B. Hidradenitis suppurativa: A comprehensive review. J. Am. Acad. Dermatol., 2009, 60(4), 539-561.
[http://dx.doi.org/10.1016/j.jaad.2008.11.911] [PMID: 19293006]
[13]
König, A.; Lehmann, C.; Rompel, R.; Happle, R. Cigarette smoking as a triggering factor of hidradenitis suppurativa.Dermatology (Basel),, 1999, 198(3), 261-264.
[http://dx.doi.org/10.1159/000018126] [PMID: 10393449]
[14]
Canoui-Poitrine, F.; Revuz, J.E.; Wolkenstein, P.; Viallette, C.; Gabison, G.; Pouget, F.; Poli, F.; Faye, O.; Bastuji-Garin, S. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J. Am. Acad. Dermatol., 2009, 61(1), 51-57.
[http://dx.doi.org/10.1016/j.jaad.2009.02.013] [PMID: 19406505]
[15]
Clark, A.K.; Quinonez, R.L.; Saric, S.; Sivamani, R.K. Hormonal therapies for hidradenitis suppurativa.Review Dermatol. Online J., 2017, 23(10), 23.
[PMID: 29469777]
[16]
Nikolakis, G.; Kyrgidis, A.; Zouboulis, C.C. Is there a role for antiandrogen therapy for hidradenitis suppurativa? a systematic review of published data. Am. J. Clin. Dermatol., 2019, 20(4), 503-513.
[http://dx.doi.org/10.1007/s40257-019-00442-w] [PMID: 31073704]
[17]
Schneider, A.M.; Cook, L.C.; Zhan, X.; Banerjee, K.; Cong, Z.; Imamura-Kawasawa, Y.; Gettle, S.L.; Longenecker, A.L.; Kirby, J.S.; Nelson, A.M. Loss of skin microbial diversity and alteration of bacterial metabolic function in Hidradenitis suppurativa. J. Invest. Dermatol. 2019.pii, S0022-202X(19)33146-X..
[18]
Hurley, H.J. Dermatologic Surgery: Principles and Practice, 2nd ed; Roenigk, R.K.; Roenigk, H.H., Jr, Eds.; Marcel Dekker: New York, , 1996; pp. 623-645.
[19]
Peris, K.; Lo Schiavo, A.; Fabbrocini, G.; Dini, V.; Patrizi, A.; Fusano, M.; Bianchi, L.; Guanziroli, E.; Guarneri, C.; Parodi, A.; Bertoldi, A.; Musumeci, M.L.; Offidani, A.; Rongioletti, F.; Pistone, G.; Malara, G.; Potenza, C.; Casari, A.; Franchi, C.; Ardigò, M.; Cusano, F.; Stingeni, L.; Amerio, P.; Mancini, L.L.; Prignano, F.; Deboli, T.; Gualberti, G.; Saragaglia, V.; Bettoli, V. HIDRA disk: Validation of an innovative visual tool to assess the burden of hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol., 2019, 33(4), 766-773.
[http://dx.doi.org/10.1111/jdv.15425] [PMID: 30633405]
[20]
Ingram, J.R.; Collier, F.; Brown, D.; Burton, T.; Burton, J.; Chin, M.F.; Desai, N.; Goodacre, T.E.E.; Piguet, V.; Pink, A.E.; Exton, L.S.; Mohd Mustapa, M.F. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br. J. Dermatol., 2019, 180(5), 1009-1017.
[http://dx.doi.org/10.1111/bjd.17537] [PMID: 30552762]
[21]
Zouboulis, C.C.; Bechara, F.G.; Fritz, K.; Kurzen, H.; Liakou, A.I.; Marsch, W.C.; Milling, A.; Nast, A.; Podda, M.; Taube, K.M.; Wienert, V.; Winkler, T. S1 guideline for the treatment of hidradenitis suppurativa / acne inversa * (number ICD-10 L73.2)]. J. Dtsch. Dermatol. Ges., 2012, 10(Suppl. 5)S1-S31.
[http://dx.doi.org/10.1111/j.1610-0387.2012.08006.x] [PMID: 22925400]
[22]
Megna, M.; Bettoli, V.; Chimenti, S.; Chiricozzi, A.; Naldi, L.; Virgili, A.; Girolomoni, G.; Monfrecola, G. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents. G. Ital. Dermatol. Venereol., 2015, 150(6), 731-739.
[PMID: 26513043]
[23]
Veraldi, S.; Guanziroli, E.; Benzecry, V.; Nazzaro, G. Multidisciplinary approach for hidradenitis suppurativa patients. G. Ital. Dermatol. Venereol., 2018, 153(3)(Suppl. 2), 18-19.
[PMID: 30468376]
[24]
Schneider-Burrus, S.; Arpa, E.; Kors, C.; Stavermann, T.; Sabat, R.; Kokolakis, G. Drug therapy of acne inversa. Hautarzt, 2018, 69(1), 58-63.
[http://dx.doi.org/10.1007/s00105-017-4094-1] [PMID: 29234829]
[25]
Vellaichamy, G.; Braunberger, T.L.; Nahhas, A.F.; Hamzavi, I.H. Surgical procedures for hidradenitis suppurativa. Cutis, 2018, 102(1), 13-16.
[PMID: 30138502]
[26]
Levoska, M.A.; Nicholson, C.L.; Hamzavi, I.H. A retrospective review of light- and laser-based management of hidradenitis suppurativa. Semin. Cutan. Med. Surg., 2017, 36(2), 67-74.
[http://dx.doi.org/10.12788/j.sder.2017.023] [PMID: 28538747]
[27]
Rowland Payne, P.C.M.E. Hidradenitis suppurativa treatment - medical or surgical? J. Eur. Acad. Dermatol. Venereol., 2019, 33(6), 981-982.
[http://dx.doi.org/10.1111/jdv.15647] [PMID: 31124252]
[28]
John, H.; Manoloudakis, N.; Stephen Sinclair, J. A systematic review of the use of lasers for the treatment of hidradenitis suppurativa. J. Plast. Reconstr. Aesthet. Surg., 2016, 69(10), 1374-1381.
[http://dx.doi.org/10.1016/j.bjps.2016.05.029] [PMID: 27496291]
[29]
Clemmensen, O.J. Topical treatment of hidradenitis suppurativa with clindamycin.Int. J. Dermatol., 1983, 22(5), 325-328.
[http://dx.doi.org/10.1111/j.1365-4362.1983.tb02150.x] [PMID: 6347922]
[30]
Jemec, G.B.; Wendelboe, P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J. Am. Acad. Dermatol., 1998, 39(6), 971-974.
[http://dx.doi.org/10.1016/S0190-9622(98)70272-5] [PMID: 9843011]
[31]
Zouboulis, C.C.; Desai, N.; Emtestam, L.; Hunger, R.E.; Ioannides, D.; Juhász, I.; Lapins, J.; Matusiak, L.; Prens, E.P.; Revuz, J.; Schneider-Burrus, S.; Szepietowski, J.C.; van der Zee, H.H.; Jemec, G.B. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J. Eur. Acad. Dermatol. Venereol., 2015, 29(4), 619-644.
[http://dx.doi.org/10.1111/jdv.12966] [PMID: 25640693]
[32]
Shirah, B.H.; Shirah, H.A. Effective modified conservative tissue preserving protocol to treat stage I axillary hidradenitis suppurativa:A prospective cohort study of 627 patients with five years follow-up. J. Dermatolog. Treat. 2017, 28(5), 458-463.
[http://dx.doi.org/10.1080/09546634.2016.1273470] [PMID: 27981857]
[33]
Schöfer, H.; Simonsen, L. Fusidic acid in dermatology: An updated review. Eur. J. Dermatol., 2010, 20(1), 6-15.
[http://dx.doi.org/10.1684/ejd.2010.0833] [PMID: 20007058]
[34]
Gener, G.; Canoui-Poitrine, F.; Revuz, J.E.; Faye, O.; Poli, F.; Gabison, G.; Pouget, F.; Viallette, C.; Wolkenstein, P.; Bastuji-Garin, S. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: A series of 116 consecutive patients. Dermatology (Basel), 2009, 219(2), 148-154.
[http://dx.doi.org/10.1159/000228334] [PMID: 19590173]
[35]
Mendonça, C.O.; Griffiths, C.E. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa.Br. J. Dermatol., , 2006, 154(5), 977-978..
[http://dx.doi.org/10.1111/j.1365-2133.2006.07155.x] [PMID: 16634904]
[36]
van der Zee, H.H.; Boer, J.; Prens, E.P.; Jemec, G.B. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology (Basel), 2009, 219(2), 143-147.
[http://dx.doi.org/10.1159/000228337] [PMID: 19590174]
[37]
Mikkelsen, P.R.; Jemec, G.B. Hidradenitis suppurativa in children and adolescents: A review of treatment options. Paediatr. Drugs, 2014, 16(6), 483-489.
[http://dx.doi.org/10.1007/s40272-014-0091-3] [PMID: 25234961]
[38]
Delaunay, J.; Villani, A.P.; Guillem, P.; Tristan, A.; Boibieux, A.; Jullien, D. Oral ofloxacin and clindamycin as an alternative to the classic rifampicin-clindamycin in hidradenitis suppurativa: Retrospective analysis of 65 patients. Br. J. Dermatol., 2018, 178(1), e15-e16.
[http://dx.doi.org/10.1111/bjd.15739] [PMID: 28626900]
[39]
Armyra, K.; Kouris, A.; Markantoni, V.; Katsambas, A.; Kontochristopoulos, G. Hidradenitis suppurativa treated with tetracycline in combination with colchicine: A prospective series of 20 patients. Int. J. Dermatol., 2017, 56(3), 346-350.
[http://dx.doi.org/10.1111/ijd.13428] [PMID: 28054351]
[40]
Join-Lambert, O.; Coignard, H.; Jais, J.P.; Guet-Revillet, H.; Poirée, S.; Fraitag, S.; Jullien, V.; Ribadeau-Dumas, F.; Thèze, J.; Le Guern, A.S.; Behillil, S.; Leflèche, A.; Berche, P.; Consigny, P.H.; Lortholary, O.; Nassif, X.; Nassif, A. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology (Basel), 2011, 222(1), 49-58.
[http://dx.doi.org/10.1159/000321716] [PMID: 21109728]
[41]
Chahine, A.A.; Nahhas, A.F.; Braunberger, T.L.; Rambhatla, P.V.; Hamzavi, I.H. Ertapenem rescue therapy in hidradenitis suppurativa. JAAD Case Rep., 2018, 4(5), 482-483.
[http://dx.doi.org/10.1016/j.jdcr.2017.12.010] [PMID: 29984290]
[42]
Pilkington, T.; Brogden, R.N. Acitretin: A review of its pharmacology and therapeutic use. Drugs, 1992, 43, 597-627.
[http://dx.doi.org/10.2165/00003495-199243040-00010]
[43]
Di Lernia, V.; Bonamonte, D.; Lasagni, C.; Belloni Fortina, A.; Cambiaghi, S.; Corazza, M.; Di Nuzzo, S.; Gisondi, P.; Panzone, M.; Guarneri, C.; Neri, I. Effectiveness and safety of acitretin in children with plaque psoriasis: A multicenter retrospective analysis. Pediatr. Dermatol., 2016, 33(5), 530-535.
[http://dx.doi.org/10.1111/pde.12940] [PMID: 27443789]
[44]
Kurayev, A.; Ashkar, H.; Saraiya, A.; Gottlieb, A.B. Hidradenitis suppurativa: Review of the pathogenesis and treatment. J. Drugs Dermatol., 2016, 15(8), 1017-1022.
[PMID: 27538005]
[45]
Piaserico, S.; Conti, A.; Lo Console, F.; De Simone, C.; Prestinari, F.; Mazzotta, A.; Gualdi, G.; Guarneri, C.; Borsari, S.; Cassano, N. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm. Venereol., 2014, 94(3), 293-297.
[http://dx.doi.org/10.2340/00015555-1719] [PMID: 24158307]
[46]
Maarouf, M.; Clark, A.K.; Lee, D.E.; Shi, V.Y. Targeted treatments for hidradenitis suppurativa: A review of the current literature and ongoing clinical trials. J. Dermatolog. Treat., 2018, 29(5), 441-449.
[http://dx.doi.org/10.1080/09546634.2017.1395806] [PMID: 29098911]
[47]
Lam, J.; Krakowski, A.C.; Friedlander, S.F. Hidradenitis suppurativa(acne inversa): Management of a recalcitrant disease. Pediatr. Dermatol., 2007, 24(5), 465-473.
[http://dx.doi.org/10.1111/j.1525-1470.2007.00544.x] [PMID: 17958790]
[48]
Matusiak, L.; Bieniek, A.; Szepietowski, J.C. Acitretin treatment for hidradenitis suppurativa: A prospective series of 17 patients. Br. J. Dermatol., 2014, 171(1), 170-174.
[http://dx.doi.org/10.1111/bjd.12884] [PMID: 24506875]
[49]
Boer, J.; Nazary, M. Long-term results of acitretin therapy for hidradenitis suppurativa.Is acne inversa also a misnomer? Br. J.Dermatol., 2011, 164(1), 170-175.
[http://dx.doi.org/10.1111/j.1365-2133.2010.10071.x] [PMID: 20874789]
[50]
Blok, J.L.; van Hattem, S.; Jonkman, M.F.; Horváth, B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: A systematic review. Br. J. Dermatol., 2013, 168(2), 243-252.
[http://dx.doi.org/10.1111/bjd.12104] [PMID: 23106519]
[51]
Tan, M.G.; Shear, N.H.; Walsh, S.; Alhusayen, R. Acitretin. J. Cutan. Med. Surg., 2017, 21(1), 48-53.
[http://dx.doi.org/10.1177/1203475416659858] [PMID: 27432818]
[52]
Verdolini, R.; Simonacci, F.; Menon, S.; Pavlou, P.; Mannello, B. Alitretinoin: A useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G. Ital. Dermatol. Venereol., 2015, 150(2), 155-162.
[PMID: 24927170]
[53]
van Straalen, K.R.; Schneider-Burrus, S.; Prens, E.P. Current and future treatment of hidradenitis suppurativa. Br. J. Dermatol., 2018. Epub ahead of print
[http://dx.doi.org/10.1111/bjd.16768] [PMID: 29981245]
[54]
Riis, P.T.; Boer, J.; Prens, E.P.; Saunte, D.M.; Deckers, I.E.; Emtestam, L.; Sartorius, K.; Jemec, G.B. Intralesional triamcinolone for flares of Hidradenitis Suppurativa (HS): A case series. J. Am. Acad. Dermatol., 2016, 75(6), 1151-1155.
[http://dx.doi.org/10.1016/j.jaad.2016.06.049] [PMID: 27692735]
[55]
Fajenbaum, K. Intralesional triamcinolone, a standard of care treatment for acute hidradenitis suppurativa, does not prove to be superior to placebo of the 2nd Annual Symposium on Hidradenitis Suppurativa, Detroit, MI, USA, 4-5 November, 2017.
[56]
Danto, J.L. Preliminary studies of the effect of hydrocortisone on hidradenitis suppurativa. J. Invest. Dermatol., 1958, 31(6), 299-300.
[http://dx.doi.org/10.1038/jid.1958.124] [PMID: 13611353]
[57]
Camisa, C.; Sexton, C.; Friedman, C. Treatment of hidradenitis suppurativa with combination hypothalamic-pituitary-ovarian and adrenal suppression. A case report. J. Reprod. Med., 1989, 34(8), 543-546.
[PMID: 2509694]
[58]
Wong, D.; Walsh, S.; Alhusayen, R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J. Am. Acad. Dermatol., 2016, 75(5), 1059-1062.
[http://dx.doi.org/10.1016/j.jaad.2016.06.001] [PMID: 27745633]
[59]
Wozel, G.; Blasum, C. Dapsone in dermatology and beyond. Arch. Dermatol. Res., 2014, 306(2), 103-124.
[http://dx.doi.org/10.1007/s00403-013-1409-7] [PMID: 24310318]
[60]
Yazdanyar, S.; Boer, J.; Ingvarsson, G.; Szepietowski, J.C.; Jemec, G.B.; Jemec, G.B. Dapsone therapy for hidradenitis suppurativa: A series of 24 patients. Dermatology (Basel), 2011, 222(4), 342-346.
[http://dx.doi.org/10.1159/000329023] [PMID: 21757878]
[61]
Ring, H.C.; Thorsen, J.; Saunte, D.M.; Lilje, B.; Bay, L.; Riis, P.T.; Larsen, N.; Andersen, L.O.; Nielsen, H.V.; Miller, I.M.; Bjarnsholt, T.; Fuursted, K.; Jemec, G.B. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls. JAMA Dermatol., 2017, 153(9), 897-905.
[http://dx.doi.org/10.1001/jamadermatol.2017.0904] [PMID: 28538949]
[62]
Verdolini, R.; Clayton, N.; Smith, A.; Alwash, N.; Mannello, B. Metformin for the treatment of hidradenitis suppurativa: A little help along the way. J. Eur. Acad. Dermatol. Venereol., 2013, 27(9), 1101-1108.
[http://dx.doi.org/10.1111/j.1468-3083.2012.04668.x] [PMID: 22882365]
[63]
Jennings, L.; Hambly, R.; Hughes, R.; Moriarty, B.; Kirby, B. Metformin use in hidradenitis suppurativa. J. Dermatolog. Treat., 2019, 20, 1-3.
[PMID: 30893570]
[64]
Di Lernia, V.; Stingeni, L.; Boccaletti, V.; Calzavara Pinton, P.G.; Guarneri, C.; Belloni Fortina, A.; Panzone, M.; Corazza, M.; Neri, I.; Cambiaghi, S.; Lasagni, C.; Ficarelli, E.; Gisondi, P. .Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis. J. Dermatolog. Treat., 2016, 27(5), 395-398.
[http://dx.doi.org/10.3109/09546634.2015.1120852] [PMID: 26571044]
[65]
Neri, I.; Calzavara Pinton, P.; Di Nuzzo, S.; Stingeni, L.; Guarneri, C.; Belloni Fortina, A.; Bonamonte, D.; Cambiaghi, S.; Lasagni, C.; Panzone, M.; Corazza, M.; Offidani, A.; Gisondi, P. Treatment patterns with systemic antipsoriatic agents in childhood psoriasis: an Italian database analysis. G. Ital. Dermatol. Venereol., 2017, 152, 327-332.
[66]
Guarneri, F.; Guarneri, C.; Marini, H. Oral lichen planus and neurogenic inflammation: New observations and therapeutic implications from four clinical cases. Dermatol. Ther. (Heidelb.), 2014, 27(4), 206-210.
[http://dx.doi.org/10.1111/dth.12118] [PMID: 24548522]
[67]
Anderson, M.D.; Zauli, S.; Bettoli, V.; Boer, J.; Jemec, G.B. Cyclosporine treatment of severe Hidradenitis suppurativa-A case series. J. Dermatolog. Treat. 2016, 27(3), 247-250.
[http://dx.doi.org/10.3109/09546634.2015.1088128] [PMID: 26406923]
[68]
Di Lernia, V. Bianchi.; Guerriero C.; Stingeni L.; Gisondi P.; Filoni A.; Guarneri C.; Belloni Fortina A.; Lasagni C.; Simonetti O.; Neri I.; Zangrilli A.; Moretta G.; Hansel K.; Casanova D.M.; Girolomoni G.; Cannavò S.P.; Bonamonte D. Adalimumab in severe plaque psoriasis of childhood: a multi-center, retrospective real-life study up to 52 weeks observation. Dermatol. Ther. (Heidelb.), 2019, 32e13091
[69]
Marcianò, I.; Randazzo, M.P.; Panagia, P.; Intelisano, R.; Sgroi, C.; Ientile, V.; Cannavò, S.; Guarneri, C.; Reitano, P.; Spina, E.; Trifirò, G. Real world use of biological drugs in patients with psoriasis/ psoriatic arthritis: A retrospective, population-based study from Southern Italy in the years 2010-2014. G. Ital. Dermatol. Venereol., 2020, 155(4), 441-451.
[http://dx.doi.org/10.23736/S0392-0488.18.05753-X] [PMID: 29582617]
[70]
Guarneri, C.; Cannavò, S.P.; Lentini, M.; Polimeni, G. Adalimumab-induced disseminated superficial porokeratosis. Ann. Pharmacother., 2011, 45(2), 280-281.
[http://dx.doi.org/10.1345/aph.1P653] [PMID: 21304021]
[71]
Savage, K.T.; Flood, K.S.; Porter, M.L.; Kimball, A.B. TNF-α inhibitors in the treatment of hidradenitis suppurativa. Ther. Adv. Chronic Dis., 2019.102040622319851640
[http://dx.doi.org/10.1177/2040622319851640] [PMID: 31191873]
[72]
Kim, E.S.; Garnock-Jones, K.P.; Keam, S.J. Adalimumab: A Review in Hidradenitis suppurativa. Am. J. Clin. Dermatol., 2016, 17(5), 545-552.
[http://dx.doi.org/10.1007/s40257-016-0220-6] [PMID: 27665300]
[73]
Matusiak, L.; Bieniek, A.; Szepietowski, J.C. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: Is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm. Venereol., 2009, 89(6), 601-603.
[http://dx.doi.org/10.2340/00015555-0749] [PMID: 19997690]
[74]
Amerio, P.; Amoruso, G.; Bardazzi, F.; Campanati, A.; Cassano, N.; Conti, A.; Gisondi, P.; Guarneri, C.; Mazzotta, A.; Piaserico, S.; Prestinari, F.; Prignano, F.; Zane, C.; de Simone, C. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. J. Dermatolog. Treat., 2013, 24(4), 305-311.
[http://dx.doi.org/10.3109/09546634.2011.654107] [PMID: 22208431]
[75]
Włodarek, K.; Ponikowska, M.; Matusiak, Ł.; Szepietowski, J.C. Biologics for hidradenitis suppurativa: An update. Immunotherapy, 2019, 11(1), 45-59.
[http://dx.doi.org/10.2217/imt-2018-0090] [PMID: 30702012]
[76]
Yazdanyar, S.; Miller, I.M.; Jemec, G.B. Hidradenitis suppurativa and Crohn’s disease: Two cases that support an association. Acta Dermatovenerol. Alp. Panonica Adriat., 2010, 19(3), 23-25.
[PMID: 20976417]
[77]
Miller, I.; Lynggaard, C.D.; Lophaven, S.; Zachariae, C.; Dufour, D.N.; Jemec, G.B. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.Br.J. Dermatol., 2011, 165(2), 391-398.
[http://dx.doi.org/10.1111/j.1365-2133.2011.10339.x] [PMID: 21457202]
[78]
Miller, I.M.; Carlson, N.; Mogensen, U.B.; Ellervik, C.; Jemec, G.B.A. A population- and hospital-based cross-sectional study of renal function in hidradenitis suppurativa. Acta Derm. Venereol., 2016, 96(1), 68-71.
[http://dx.doi.org/10.2340/00015555-2072] [PMID: 25710874]
[79]
Kimball, A.B.; Sobell, J.M.; Zouboulis, C.C.; Gu, Y.; Williams, D.A.; Sundaram, M.; Teixeira, H.D.; Jemec, G.B. HiSCR (Hidradenitis Suppurativa Clinical Response): A novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J. Eur. Acad. Dermatol. Venereol., 2016, 30(6), 989-994.
[http://dx.doi.org/10.1111/jdv.13216] [PMID: 26201313]
[80]
Kimball, A.B.; Okun, M.M.; Williams, D.A.; Gottlieb, A.B.; Papp, K.A.; Zouboulis, C.C.; Armstrong, A.W.; Kerdel, F.; Gold, M.H.; Forman, S.B.; Korman, N.J.; Giamarellos-Bourboulis, E.J.; Crowley, J.J.; Lynde, C.; Reguiai, Z.; Prens, E.P.; Alwawi, E.; Mostafa, N.M.; Pinsky, B.; Sundaram, M.; Gu, Y.; Carlson, D.M.; Jemec, G.B. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N. Engl. J. Med., 2016, 375(5), 422-434.
[http://dx.doi.org/10.1056/NEJMoa1504370] [PMID: 27518661]
[81]
Guarneri, F.; Guarneri, C.; Guarneri, B. Biologic agents in the treatment of psoriasis. Recent Pat. Inflamm. Allergy Drug Discov., 2007, 1(3), 193-217.
[http://dx.doi.org/10.2174/187221307782418919] [PMID: 19075983]
[82]
Dattilo, G.; Borgia, F.; Guarneri, C.; Casale, M.; Bitto, R.; Morabito, C.; Signorelli, S.; Katsiki, N.; Cannavò, S.P. Cardiovascular risk in psoriasis: Current state of the art. Curr. Vasc. Pharmacol. 2019, 17(1), 85-91.
[http://dx.doi.org/10.2174/1570161115666171116163816] [PMID: 29149819]
[83]
Lim, S.Y.D.; Oon, H.H. Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics, 2019, 13, 53-78.
[http://dx.doi.org/10.2147/BTT.S199862] [PMID: 31190730]
[84]
Moriarty, B.; Jiyad, Z.; Creamer, D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br. J. Dermatol., 2014, 170(4), 986-987.
[http://dx.doi.org/10.1111/bjd.12713] [PMID: 24641123]
[85]
Grant, A.; Gonzalez, T.; Montgomery, M.O.; Cardenas, V.; Kerdel, F.A. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial. J. Am. Acad. Dermatol., 2010, 62(2), 205-217.
[http://dx.doi.org/10.1016/j.jaad.2009.06.050] [PMID: 20115947]
[86]
Di Lernia, V.; Guarneri, C.; Stingeni, L.; Gisondi, P.; Bonamonte, D.; Pinton, C.P.G.; Offidani, A.; Hansel, K.; Girolomoni, G.; Filoni, A.; Fortina, B.A.; Ficarelli, E.; Cannavò, S.P. Effectiveness of etanercept in children with plaque psoriasis in real practice: A oneyear multicenter retrospective study. J. Dermatolog. Treat. 2018, 29(3), 217-219.
[http://dx.doi.org/10.1080/09546634.2017.1364692] [PMID: 28783991]
[87]
Tchernev, G.; Guarneri, C.; Bevelacqua, V.; Wollina, U. Carcinoma cuniculatum in course of etanercept: Blocking autoimmunity but propagation of carcinogenesis? Int. J. Immunopathol. Pharmacol., 2014, 27(2), 261-266.
[http://dx.doi.org/10.1177/039463201402700213] [PMID: 25004838]
[88]
Guarneri, C.; Russo, M.; Mazzeo, A.; Cannavò, S.P. Etanercept for psoriasis and psoriatic arthritis in a patient with Charcot-Marie-Tooth disease. Ann. Pharmacother., 2014, 48(4), 550-551.
[http://dx.doi.org/10.1177/1060028013513226] [PMID: 24658637]
[89]
Guarneri, C.; Polimeni, G. Nicolau syndrome following etanercept administration.Am. J. Clin. Dermatol.,, 2010, 11(Suppl. 1), 51-52.
[http://dx.doi.org/10.2165/1153426-S0-000000000-00000] [PMID: 20586511]
[90]
Guarneri, C.; Polimeni, G.; Nunnari, G. Pityriasis rosea during etanercept therapy. Eur. Rev. Med. Pharmacol. Sci., 2009, 13(5), 383-387.
[PMID: 19961045]
[91]
Adams, D.R.; Yankura, J.A.; Fogelberg, A.C.; Anderson, B.E. Treatment of hidradenitis suppurativa with etanercept injection. Arch. Dermatol., 2010, 146(5), 501-504.
[http://dx.doi.org/10.1001/archdermatol.2010.72] [PMID: 20479297]
[92]
Marasca, C.; Annunziata, M.C.; Napolitano, M.; Fabbrocini, G. Unconventional therapies for hidradenitis suppurativa.Expert Rev. Clin. Pharmacol.,, 2018, 11(9), 879-887.
[http://dx.doi.org/10.1080/17512433.2018.1509706] [PMID: 30136871]
[93]
Hutas, G. Golimumab, a fully human monoclonal antibody against TNF alpha. Curr. Opin. Mol. Ther., 2008, 10(4), 393-406.
[PMID: 18683105]
[94]
Guarneri, C.; Bevelacqua, V.; Patterson, J.W.; Tchernev, G. Cutaneous and visceral leishmaniasis during anti-TNFα therapy. Wien. Med. Wochenschr., 2017, 167(3-4), 78-82.
[http://dx.doi.org/10.1007/s10354-016-0527-1] [PMID: 27832423]
[95]
van der Zee, H.H.; Prens, E.P. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: A case report. Dermatology (Basel), 2013, 226(2), 97-100.
[http://dx.doi.org/10.1159/000343221] [PMID: 23713053]
[96]
Tursi, A. Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab. Dig. Liver Dis., 2016, 48(12), 1511-1512.
[http://dx.doi.org/10.1016/j.dld.2016.09.010] [PMID: 27793616]
[97]
Porter, M.L.; Golbari, N.M.; Lockwood, S.J.; Kimball, A.B. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. Semin. Cutan. Med. Surg., 2018, 37(3), 182-189.
[http://dx.doi.org/10.12788/j.sder.2018.042] [PMID: 30215636]
[98]
Frew, J.W.; Hawkes, J.E.; Krueger, J.G. Topical, systemic and biologic therapies in hidradenitis suppurativa: Pathogenic insights by examining therapeutic mechanisms. Ther. Adv. Chronic Dis., 2019, 102040622319830646
[http://dx.doi.org/10.1177/2040622319830646] [PMID: 30854183]
[99]
Tzanetakou, V.; Kanni, T.; Giatrakou, S.; Katoulis, A.; Papadavid, E.; Netea, M.G.; Dinarello, C.A.; van der Meer, J.W.M.; Rigopoulos, D.; Giamarellos-Bourboulis, E.J. Safety and efficacy of anakinra in severe hidradenitis suppurativa: A randomized clinical trial. JAMA Dermatol., 2016, 152(1), 52-59.Erratum in: JAMA Dermatol. 2017, 153, 950.
[http://dx.doi.org/10.1001/jamadermatol.2015.3903] [PMID: 26579854]
[100]
André, R.; Marescassier, H.; Gabay, C.; Pittet, B.; Laffitte, E. Long-term therapy with anakinra in hidradenitis suppurativa in three patients. Int. J. Dermatol., 2019, 58(11), e208-e209. Epub ahead of print
[http://dx.doi.org/10.1111/ijd.14596] [PMID: 31353451]
[101]
Kanni, T.; Argyropoulou, M.; Spyridopoulos, T.; Pistiki, A.; Stecher, M.; Dinarello, C.A.; Simard, J.; Giamarellos-Bourboulis, E.J. MABp1 targeting IL-1α for moderate to severe hidradenitis suppurativa not eligible for adalimumab: A randomized study. J. Invest. Dermatol., 2018, 138(4), 795-801.
[http://dx.doi.org/10.1016/j.jid.2017.10.030] [PMID: 29129600]
[102]
Houriet, C.; Seyed Jafari, S.M.; Thomi, R.; Schlapbach, C.; Borradori, L.; Yawalkar, N.; Hunger, R.E. canakinumab for severe hidradenitis suppurativa: Preliminary experience in 2 cases. JAMA Dermatol. 2017, 153(11), 1195-1197.
[http://dx.doi.org/10.1001/jamadermatol.2017.2392] [PMID: 28854317]
[103]
Sun, N.Z.; Ro, T.; Jolly, P.; Sayed, C.J. Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa. J. Clin. Aesthet. Dermatol., 2017, 10(9), 36-38.
[PMID: 29344326]
[104]
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa - Full Text View -ClinicalTrials.gov., 2013.https://clinicaltrials.gov/ct2/show/study/NCT01838499?term=medi8968&cond=Hidradenitis&rank=1
[105]
Melnik, B.C.; John, S.M.; Chen, W.; Plewig, G. T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: The link to hair follicle dissection, obesity, smoking and autoimmune comorbidities. Br. J. Dermatol., 2018, 179(2), 260-272.
[http://dx.doi.org/10.1111/bjd.16561] [PMID: 29573406]
[106]
Yao, Y.; Thomsen, S.F. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa. Dermatol. Online J., 2017, 23(7), 7.
[PMID: 29469692]
[107]
Cannavò, S.P.; Postorino, E.; Aragona, E.; Bartolotta, A.; Papaianni, V.; Guarneri, C. Secukinumab for plaque psoriasis with ocular comorbidity: A clinical experience. J. Dermatolog. Treat., 2018, 29(sup1), 9-11.
[http://dx.doi.org/10.1080/09546634.2018.1527995] [PMID: 30247938]
[108]
Cannavò, S.P.; Papaianni, V.; Bartolotta, A.; Guarneri, C. Secukinumab for psoriasis in a patient with familial Mediterranean fever. Dermatol. Ther. (Heidelb.), 2019, 32(6)e13122
[http://dx.doi.org/10.1111/dth.13122] [PMID: 31614038]
[109]
Matusiak, Ł.; Szczęch, J.; Bieniek, A.; Nowicka-Suszko, D.; Szepietowski, J.C. Increased Interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J. Am. Acad. Dermatol., 2017, 76(4), 670-675.
[http://dx.doi.org/10.1016/j.jaad.2016.10.042] [PMID: 28041632]
[110]
Currado, D.; Margiotta, D.; Conforti, C.; Coppola, R.; Panasiti, V.; Afeltra, A.; Navarini, L. New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: A case report. Scand. J. Rheumatol., 2019, 2, 1-2.
[PMID: 31262212]
[111]
Conforti, C.; Currado, D.; Vezzoni, R.; Corneli, P.; Bussani, R.; Navarini, L.; Magaton-Rizzi, G.; Fischetti, F.; Di Meo, N.; Zalaudek, I. I. Erythema multiforme induced by secukinumab: Clinical, dermoscopic, and histological features. J. Clin. Rheumatol., 2020.Epub ahead of print
[http://dx.doi.org/10.1097/RHU.0000000000001315] [PMID: 31977648]
[112]
Galluzzo, M.; D’Adamio, S.; Campione, E.; Mazzilli, S.; Bianchi, L.; Talamonti, M. A clinical case of severe disease burden: An erythrodermic psoriatic patient treated with secukinumab. J. Dermatolog. Treat. 2018, 26, 1-11.
[http://dx.doi.org/10.1080/09546634.2018.1524818] [PMID: 30256706]
[113]
Theut Riis, P.; Thorlacius, L.R.; Jemec, G.B. Investigational drugs in clinical trials for hidradenitis suppurativa. Expert Opin. Investig.Drugs, 2018, 27(1), 43-53.
[http://dx.doi.org/10.1080/13543784.2018.1412430] [PMID: 29188733]
[114]
Schuch, A.; Fischer, T.; Boehner, A.; Biedermann, T.; Volz, T. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab. Acta Derm. Venereol., 2018, 98(1), 151-152.
[http://dx.doi.org/10.2340/00015555-2794] [PMID: 28902952]
[115]
Thorlacius, L.; Theut Riis, P.; Jemec, G.B.E. Severe hidradenitis suppurativa responding to treatment with secukinumab: A case report. Br. J. Dermatol., 2018, 179(1), 182-185.
[http://dx.doi.org/10.1111/bjd.15769] [PMID: 28654150]
[116]
Jørgensen, A.R.; Yao, Y.; Thomsen, S.F. Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case Rep. Dermatol. Med., 2018.20188685136
[http://dx.doi.org/10.1155/2018/8685136] [PMID: 29850284]
[117]
Giuseppe, P.; Nicola, P.; Valentina, C.; Elena, C.; Salvatrice, C.; Rosario, G.; Rita, B.M. A case of moderate hidradenitis suppurativa and psoriasis treated with secukinumab. Ann. Dermatol., 2018, 30(4), 462-464.
[http://dx.doi.org/10.5021/ad.2018.30.4.462] [PMID: 30065588]
[118]
Bassas-Vila, J.; González Lama, Y. Hidradenitis suppurativa and perianal Crohn disease: Differential diagnosis. Actas Dermosifiliogr., 2016, 107(Suppl. 2), 27-31.
[http://dx.doi.org/10.1016/S0001-7310(17)30006-6] [PMID: 28081767]
[119]
Prussick, L.; Rothstein, B.; Joshipura, D.; Saraiya, A.; Turkowski, Y.; Abdat, R.; Alomran, A.; Zancanaro, P.; Kachuk, C.; Dumont, N.; Gottlieb, A.B.; Rosmarin, D. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br. J. Dermatol., 2019, 181(3), 609-611.
[http://dx.doi.org/10.1111/bjd.17822] [PMID: 30801662]
[120]
Egeberg, A.; Andersen, Y.M.F.; Halling-Overgaard, A.S.; Alignahi, F.; Thyssen, J.P.; Burge, R.; Mallbris, L. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J. Eur. Acad. Dermatol. Venereol., 2020, 34(1), 39-46.
[PMID: 31465593]
[121]
Mease, P. Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis. Curr. Rheumatol. Rep., 2019, 21(7), 35.
[http://dx.doi.org/10.1007/s11926-019-0830-0] [PMID: 31172311]
[122]
Odorici, G.; Pellacani, G.; Conti, A. Ixekizumab in hidradenitis suppurativa: A case report in a psoriatic patient. G. Ital. Dermatol. Venereol., 2019.Epub ahead of print.
[PMID: 30636397]
[123]
Chiricozzi, A.; De Simone, C.; Fossati, B.; Peris, K. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: Evaluating bimekizumab and its therapeutic potential. Psoriasis (Auckl), 2019, 9, 29-35.
[http://dx.doi.org/10.2147/PTT.S179283] [PMID: 31214486]
[124]
Glatt, S.; Taylor, P.C.; McInnes, I.B.; Schett, G.; Landewé, R.; Baeten, D.; Ionescu, L.; Strimenopoulou, F.; Watling, M.I.L.; Shaw, S. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: A proof-of-concept study. Ann. Rheum. Dis., 2019, 78(8), 1033-1040.
[http://dx.doi.org/10.1136/annrheumdis-2018-214943] [PMID: 31177099]
[125]
Natsis, N.E.; Gottlieb, A.B. Bimekizumab for the treatment of psoriatic disease. Expert Opin. Biol. Ther., 2018, 18(12), 1193-1197.
[http://dx.doi.org/10.1080/14712598.2018.1538351] [PMID: 30332893]
[126]
A Study to Test the Efficacy,Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.- Full Text View - ClinicalTrials.gov., 2017 https://clinicaltrials.gov/ct2/show/NCT03248531?term=bimekizumab& \
[127]
Efficacy Safetyand Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients - Full Text View - ClinicalTrials. gov., 2015.https://clinicaltrials.gov/ct2/show/study/NCT02421172?term=cjm112&cond=Hidradenitis&
[128]
Guarneri, C.; Lentini, M.; Polimeni, G.; Giuffrida, R.; Cannavò, S.P. Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus. Br. J. Clin. Pharmacol., 2016, 81(4), 792-794.
[http://dx.doi.org/10.1111/bcp.12837] [PMID: 26616890]
[129]
Schlapbach, C.; Hänni, T.; Yawalkar, N.; Hunger, R.E. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J. Am. Acad. Dermatol., 2011, 65(4), 790-798.
[http://dx.doi.org/10.1016/j.jaad.2010.07.010] [PMID: 21641076]
[130]
Blok, J.L.; Li, K.; Brodmerkel, C.; Horvátovich, P.; Jonkman, M.F.; Horváth, B. Ustekinumab in hidradenitis suppurativa: Clinical results and a search for potential biomarkers in serum. Br. J. Dermatol., 2016, 174(4), 839-846.
[http://dx.doi.org/10.1111/bjd.14338] [PMID: 26641739]
[131]
Casseres, R.G.; Kahn, J.S.; Her, M.J.; Rosmarin, D. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review. J. Am. Acad. Dermatol., 2019, 81(1), 265-267.
[http://dx.doi.org/10.1016/j.jaad.2018.12.017] [PMID: 30562567]
[132]
Kovacs, M.; Podda, M. Guselkumab in the treatment of severe hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol., 2019, 33, 140-141.
[http://dx.doi.org/10.1111/jdv.15368]
[133]
Ceccarelli, M.; Venanzi Rullo, E.; Vaccaro, M.; Facciolà, A.; d’Aleo, F.; Paolucci, I.A.; Cannavò, S.P.; Cacopardo, B.; Pinzone, M.R.; Pellicanò, G.F.; Condorelli, F.; Nunnari, G.; Guarneri, C. HIV-associated psoriasis: Epidemiology, pathogenesis, and management. Dermatol. Ther. (Heidelb.), 2019, 32(2)e12806
[http://dx.doi.org/10.1111/dth.12806] [PMID: 30588732]
[134]
Berman, H.S.; Villa, N.M.; Shi, V.Y.; Hsiao, J.L. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease. J. Dermatolog. Treat., 2019, 25, 1-3.
[http://dx.doi.org/10.1080/09546634.2019.1654067] [PMID: 31389737]
[135]
Kanni, T.; Zenker, O.; Habel, M.; Riedemann, N.; Giamarellos-Bourboulis, E.J. Complement activation in hidradenitis suppurativa: A new pathway of pathogenesis? Br. J. Dermatol., 2018, 179(2), 413-419.
[http://dx.doi.org/10.1111/bjd.16428] [PMID: 29405257]
[136]
Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa - Full Text View - ClinicalTrials.gov., 2016.https://clinicaltrials.gov/ct2/show/NCT03001622?term=ifx+1&cond=Hidradenitis&rank=1
[137]
Efficacy and Safety Study of IFX-1 in Patients with Moderate to Severe Hidradenitis Suppurativa (HS)(SHINE),. 2018.https://clinicaltrials.gov/ct2/show/NCT03487276
[138]
Takahashi, K.; Yanagi, T.; Kitamura, S.; Hata, H.; Imafuku, K.; Iwami, D.; Hotta, K.; Morita, K.; Shinohara, N.; Shimizu, H. Successful treatment of hidradenitis suppurativa with rituximab for a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediated rejection. J. Dermatol., 2018, 45(5), e116-e117.
[http://dx.doi.org/10.1111/1346-8138.14144] [PMID: 29168221]
[139]
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa - Full Text View - Clinicaltrials. gov, 2018.https://clinicaltrials.gov/ct2/show/NCT03607487
[140]
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa - Full Text View - Clinicaltrials.gov., 2018.https://clinicaltrials.gov/ct2/show/NCT03569371
[141]
Maloney, N.J.; Zhao, J.; Tegtmeyer, K.; Lee, E.Y.; Cheng, K. Off-label studies on apremilast in dermatology: A review. J. Dermatolog. Treat., 2019, 2, 1-10.
[PMID: 30935262]
[142]
Weber, P.; Seyed Jafari, S.M.; Yawalkar, N.; Hunger, R.E. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients. J. Am. Acad. Dermatol., 2017, 76(6), 1189-1191.
[http://dx.doi.org/10.1016/j.jaad.2017.02.026] [PMID: 28522043]
[143]
Kerdel, F.R.; Azevedo, F.A.; Kerdel Don, C.; Don, F.A.; Fabbrocini, G.; Kerdel, F.A. apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study. J. Drugs Dermatol., 2019, 18(2), 170-176.
[PMID: 30811140]
[144]
Vossen, A.R.J.V.; van der Zee, H.H.; Davelaar, N.; Mus, A.M.C.; van Doorn, M.B.A.; Prens, E.P. Apremilast for moderate hidradenitis suppurativa: No significant change in lesional skin inflammatory biomarkers. J. Eur. Acad. Dermatol. Venereol., 2019, 33(4), 761-765.
[http://dx.doi.org/10.1111/jdv.15354] [PMID: 30451329]
[145]
Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa - FullText View - ClinicalTrials gov.. 2016.https://clinicaltrials.gov/ct2/show/NCT02695212?term=apremilast&cond=Hidradenitis&rank=
[146]
Luo, D.; Tan, Y.; Cheng, Q.; Wu, J.; Lei, X. Photodynamic therapy combined with surgery for hidradenitis suppurativa: A case report. Photodiagnosis Photodyn. Ther.,, 2019, 27pii, S1572-1000(19),30194-2..
[http://dx.doi.org/10.1016/j.pdpdt.2019.07.024]
[147]
Borgia, F.; Giuffrida, R.; Caradonna, E.; Vaccaro, M.; Guarneri, F.; Cannavò, S.P. Early and late onset side effects of photodynamic therapy. Biomedicines, 2018, 6(1), 12.
[http://dx.doi.org/10.3390/biomedicines6010012] [PMID: 29382133]
[148]
Mordon, S. Treating hidradenitis suppurativa with photodynamic therapy. J. Cosmet. Laser Ther., 2018, 20(4), 223-228.
[http://dx.doi.org/10.1080/14764172.2017.1400169] [PMID: 29192803]
[149]
Suárez Valladares, M.J.; Eiris Salvado, N.; Rodríguez Prieto, M.A. Treatment of hidradenitis suppurativa with intralesional photodynamic therapy with 5-aminolevulinic acid and 630nm laser beam. J. Dermatol. Sci., 2017, 85(3), 241-246.
[http://dx.doi.org/10.1016/j.jdermsci.2016.12.014] [PMID: 28034606]
[150]
Bu, W.; Xu, X.; Wang, Y.; Huang, L.; Zeng, R.; Chen, X.; Fang, F. Surgery combined with photodynamic therapy for the treatment of Hidradenitis suppurativa: A report of 7 cases. Photodiagn. Photodyn. Ther., 2017, 18, 46-49.
[http://dx.doi.org/10.1016/j.pdpdt.2017.01.176] [PMID: 28119142]
[151]
Dalrymple, J.C.; Monaghan, J.M. Treatment of hidradenitis suppurativa with the carbon dioxide laser. Br. J. Surg., 1987, 74(5), 420.
[http://dx.doi.org/10.1002/bjs.1800740535] [PMID: 3109537]
[152]
Lapins, J.; Marcusson, J.A.; Emtestam, L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping-secondary intention technique. Br. J. Dermatol., 1994, 131(4) ], 551-556.
[http://dx.doi.org/10.1111/j.1365-2133.1994.tb08559.x] [PMID: 7947209]
[153]
Lapins, J.; Sartorius, K.; Emtestam, L. Scanner-assisted carbon dioxide laser surgery: A retrospective follow-up study of patients with hidradenitis suppurativa. J. Am. Acad. Dermatol., 2002, 47(2), 280-285.
[http://dx.doi.org/10.1067/mjd.2002.124601] [PMID: 12140476]
[154]
Madan, V.; Hindle, E.; Hussain, W.; August, P.J. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser.Br. J. Dermatol., , 2008, 159(6), 1309-1314.
[http://dx.doi.org/10.1111/j.1365-2133.2008.08932.x] [PMID: 19036028]
[155]
Mikkelsen, P.R.; Dufour, D.N.; Zarchi, K.; Jemec, G.B. Recurrence rate and patient satisfaction of CO2 laser evaporation of lesions in patients with hidradenitis suppurativa: A retrospective study.Dermatol. Surg.,, 2015, 41(2), 255-260.
[http://dx.doi.org/10.1097/DSS.0000000000000264] [PMID: 25654196]
[156]
Saunte, D.M.; Lapins, J. Lasers and Intense Pulsed Light Hidradenitis Suppurativa. Dermatol. Clin., 2016, 34(1), 111-119.
[http://dx.doi.org/10.1016/j.det.2015.08.001] [PMID: 26617364]
[157]
Mahmoud, B.H.; Tierney, E.; Hexsel, C.L.; Pui, J.; Ozog, D.M.; Hamzavi, I.H. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium: Yttrium-aluminium-garnet laser. J. Am. Acad. Dermatol., 2010, 62(4), 637-645.
[http://dx.doi.org/10.1016/j.jaad.2009.07.048] [PMID: 20227579]
[158]
Xu, L.Y.; Wright, D.R.; Mahmoud, B.H.; Ozog, D.M.; Mehregan, D.A.; Hamzavi, I.H. Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd: YAG laser treatment. Arch. Dermatol., 2011, 147(1), 21-28.
[http://dx.doi.org/10.1001/archdermatol.2010.245] [PMID: 20855672]
[159]
Tierney, E.; Mahmoud, B.H.; Hexsel, C.; Ozog, D.; Hamzavi, I. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser.Dermatol. Surg.,, 2009, 35(8), 1188-1198.
[http://dx.doi.org/10.1111/j.1524-4725.2009.01214.x] [PMID: 19438670]
[160]
Clinicaltrials.gov; 2018.https://clinicaltrials.gov(accessed on November 9, 2019)..


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 22
ISSUE: 1
Year: 2021
Published on: 04 May, 2020
Page: [59 - 72]
Pages: 14
DOI: 10.2174/1389201021666200505100556
Price: $65

Article Metrics

PDF: 59
HTML: 3